MedTrace Logo

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

NCT03728842 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2025-10-27

No results posted yet for this study

Summary

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

Conditions

  • Melanoma; Renal Cell Carcinoma

Interventions

OTHER

Blood collection for laboratory studies

Peripheral whole blood will be collected

OTHER

Data collection from medical record

Clinical data such as demographics and cancer characteristics, history and treatment will be collected

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Theodore Logan, MD · Indiana University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-04
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03728842 on ClinicalTrials.gov